Jefferies Group’s Palvella Therapeutics PVLA Stock Holding History

Jefferies Group’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-141	Closed	-$38K	–	3081
2019 Q3	$38K	Buy	+141	New	+$54.6K	﹤0.01%	2600

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's PVLA Position: Q4 2019 in Review

Jefferies Group sold out of Palvella Therapeutics (PVLA) in Q4 2019, closing a stake of 141 shares — an estimated $38K sold.

Jefferies Group first reported a position in PVLA in Q3 2019 and held it in 1 quarter. The position peaked at $38K in Q3 2019. 97 funds tracked by Wall St. Rank hold PVLA as of Q4 2019.

Jefferies Group reported no remaining Palvella Therapeutics position as of Q4 2019 after selling out during the quarter.
Jefferies Group sold 141 Palvella Therapeutics shares in Q4 2019, an estimated $38K.
Jefferies Group first reported a position in Palvella Therapeutics in Q3 2019 and held it in 1 quarter.
Jefferies Group's Palvella Therapeutics position peaked at $38K in Q3 2019.
97 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.